Novel therapies for Multiple Sclerosis
A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Neurorehabilitation".
Deadline for manuscript submissions: closed (20 November 2020) | Viewed by 7957
Special Issue Editor
Interests: Neurology; Neurorehabilitation; Multiple Sclerosis; Multiple Sclerosis Treatment; Quality of Life; Cognitive impairment; Neuroepidemiology; Clinical immunology; Amyotrophic Lateral Sclerosis; NMOSD; Myastenia Gravis; Parkinson disease; Epilepsy; Patient centricity
Special Issue Information
Dear Colleagues,
There is no curative treatment available for multiple sclerosis (MS), and the current therapeutic strategy is finalized to reduce the risk of relapses and, potentially, disability progression. The field of MS therapeutics is evolving rapidly. In the last decades, new disease modifying therapies (DMTs) have been added to our armamentarium. Most DMTS are currently approved either as first line therapy or second line therapy, to treat patients with relapsing forms of MS. Fewer DMTs are approved and used to treat both primary and secondary progressive MS patients.
Beta interferons, glatiramer acetate, azathioprine, teriflunomide, dimethyl-fumarate, natalizumab, fingolimod, and alemtuzumab, as well as ocrelizumab, cladribine, siponimod, rituximab, ozanimod, ofatumumab, and autologous stem cell transplantation show different mechanisms of action that can suppress or modulate the dysregulated immune system, limiting neuroinflammation, preventing new relapses and new MRI lesions, and, finally, reducing disability worsening.
With this great variety of therapeutic options, neurologists may face new challenges selecting early more effective and personalized treatments that do not carry over a potential safety risk. Nonetheless, there is a need to thoroughly select and strictly monitor safety programs, towards a complete cessation of any disease activity. There is also a need to think of the first treatment choice for how to sequence in case of treatment failure, poor tolerability, reduced adherence, or safety concerns.
This Issue aims to provide useful guidance on personalized treatment selection based on the newest paradigms of MS management.
Prof. Dr. Francesco Patti
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Novel therapies for Multiple Sclerosis
- Induction/Escalation
- Sequencing therapies
- Monoclonal antibodies
- Oral therapies
- Neuropathology:
- Neuroinflammation
- Neurodegeneration
- Neuroprotection
- Remyelination
